Editas Medicine (EDIT)
About
Business overview of Editas Medicine (EDIT)
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Key Insights
Critical company metrics and information
Share Price
$1.34Market Cap
$110.61 MillionTotal Outstanding Shares
82.55 Million SharesTotal Employees
226Dividend
No dividendIPO Date
February 3, 2016SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQType
Common StockPhone Number
617-401-9000Address
11 hurley st., Cambridge, MA, 02141Homepage
https://www.editasmedicine.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $1.03 Million |
| Net Cash Flow From Financing Activities | $1.03 Million |
| Net Cash Flow From Operating Activities, Continuing | $-181.76 Million |
| Net Cash Flow From Investing Activities | $194.03 Million |
| Net Cash Flow From Operating Activities | $-181.76 Million |
| Net Cash Flow, Continuing | $13.29 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Operating Income/Loss | $-228.52 Million |
| Costs And Expenses | $290.28 Million |
| Operating Expenses | $290.28 Million |
| Nonoperating Income/Loss | $17.95 Million |
| Net Income/Loss | $-210.57 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Parent | $175.63 Million |
| Equity | $175.63 Million |
| Fixed Assets | $15.42 Million |
| Liabilities And Equity | $327.57 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Noncurrent Assets | $56.43 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2025 Financhle. All Rights Reserved.